Two structurally independent imaging methods pointing in the same direction at 24 weeks is the kind of signal that turns a Phase 2 into a planning document. INmune Bio’s MINDFuL trial, which completed enrollment of 208 patients with early Alzheimer’s disease in November 2024, has now produced statistically significant treatment differences (p < 0.01) on white matter myelin integrity at Week 24 in the modified intent-to-treat population, corroborated by cortical disarray measurement changes in gray matter captured through a completely separate acquisition sequence and processing pipeline. That methodological independence matters enormously: when chi-separation, which uses magnetic susceptibility, and CDM, which uses water diffusion, both shift in the same treatment direction, the odds of a shared artifact explaining the pattern collapse sharply.
The design logic here reflects a deliberate bet on neuroinflammation biology rather than amyloid clearance. XPro1595 (pegipanermin) selectively neutralizes soluble TNF without blocking transmembrane TNF, preserving the immune functions that blanket TNF suppression disrupts. The hypothesis is that pathological neuroinflammation drives early myelin degradation and gray matter disorganization, and that catching this process before volumetric atrophy becomes visible creates a real therapeutic window. The Week 24 results appear to validate that the drug reaches its target and alters microstructure at a stage when conventional MRI measures such as hippocampal volume would likely register nothing. Larger effect sizes in the biomarker-enriched subgroup, selected for neuroinflammatory signatures, reinforce the precision-medicine framing INmune Bio has built around patient selection.
Context matters for understanding what comes next. The approved landscape for early Alzheimer’s now includes anti-amyloid antibodies such as lecanemab and donanemab, which work through a different mechanism entirely. XPro’s myelin and microstructural data position it as a potential complement rather than a direct substitute, and FDA Fast Track designation for the drug in early Alzheimer’s, covering mild cognitive impairment and mild dementia, reflects the agency’s acknowledgment of residual unmet need in the space. INmune Bio also reports successful regulatory alignment from an End-of-Phase 2 meeting, with an integrated Phase 2b/3 seamless adaptive registrational program planned.
The full poster at AAIC on July 12 in London will include longitudinal analyses and subgroup breakdowns that the topline readout from June did not. The one number worth watching when that poster drops is the effect size differential between the biomarker-enriched subgroup and the broader mITT population, because the magnitude of that gap will determine how tightly INmune Bio can draw its patient selection criteria heading into the registrational design.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
